To Demonstrate the Relative Bioavailability of Atenolol Tablets

Overview

To demonstrate the relative bioavailability of Atenolol tablets.

Full Title of Study: “Bioavailability of Atenolol Tablets”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 1989

Interventions

  • Drug: Atenolol Tablets 100 mg (Cord Laboratories)
  • Drug: Atenolol Tablets 100 mg (Stuart Pharmaceutical)

Arms, Groups and Cohorts

  • Experimental: 1
    • Atenolol Tablets 100 mg (Cord Laboratories)
  • Active Comparator: 2
    • Atenolol Tablets 100 mg (Stuart Pharmaceutical)

Clinical Trial Outcome Measures

Primary Measures

  • Bioequivalence based on AUC and Cmax
    • Time Frame: 11 days

Participating in This Clinical Trial

Inclusion Criteria

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C. – Treatment for drug or alcohol dependence.

Gender Eligibility: Male

Minimum Age: 19 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Sandoz
  • Provider of Information About this Clinical Study
    • Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc.
  • Overall Official(s)
    • Rudolph C. Cane, Jr., M.D., Principal Investigator, PharmaKinetics Laboratories Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.